Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation.
The Heparanase pipeline drugs market research report provides an analysis of the Heparanase drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heparanase and features dormant and discontinued projects.
Key Therapy Areas of the Heparanase Pipeline Drugs Market
Some of the therapy areas of the Heparanase pipeline drugs market are Oncology, Infectious Disease, Ophthalmology, Hematological Disorders, and Immunology.
Heparanase Pipeline Drugs Market, by Therapy Areas
For more insights on key therapy areas, download a free report sample
Key Mechanisms of Action in the Heparanase Pipeline Drugs Market
The key mechanism of action of the Heparanase pipeline drugs market is Heparanase Inhibitor.
Key Routes of Administration in the Heparanase Pipeline Drugs Market
The routes of administration in the Heparanase pipeline drugs market are subcutaneous, intravenous, and oral.
Heparanase Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Key Molecule Types in the Heparanase Pipeline Drugs Market
The molecule types in the Heparanase pipeline drugs market are Small Molecule, Polysaccharide, Peptide, and Synthetic Peptide.
Heparanase Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Key Companies in the Heparanase Pipeline Drugs Market
Some of the key companies in the Heparanase pipeline drugs market are B-Side Pharma Ltd, Beta Therapeutics Pty Ltd, CarboMimetics, HepaRx Ltd, Johnson & Johnson, Leadiant Biosciences Inc, Shenzhen Hepalink Pharmaceutical Group Co Ltd, and Zucero Therapeutics Ltd.
Heparanase Pipeline Drugs Market, by Companies
For more insights on companies, download a free report sample
Heparanase Pipeline Drugs Market Report Overview
Key Therapy Areas | Oncology, Infectious Disease, Ophthalmology, Hematological Disorders, and Immunology |
Key Mechanisms of Action | Heparanase Inhibitor |
Key Routes of Administration | Subcutaneous, Intravenous, and Oral |
Key Molecule Types | Small Molecule, Polysaccharide, Peptide and Synthetic Peptide |
Key Companies | B-Side Pharma Ltd, Beta Therapeutics Pty Ltd, CarboMimetics, HepaRx Ltd, Johnson & Johnson, Leadiant Biosciences Inc, Shenzhen Hepalink Pharmaceutical Group Co Ltd and Zucero Therapeutics Ltd |
Scope
- The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
- The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects
- The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Beta Therapeutics Pty Ltd
CarboMimetics
HepaRx Ltd
Johnson & Johnson
Leadiant Biosciences Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Zucero Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the therapy areas of the Heparanase pipeline drugs market?
Some of the therapy areas of the Heparanase pipeline drugs market are Oncology, Infectious Disease, Ophthalmology, Hematological Disorders and Immunology.
-
What is the mechanisms of action of the Heparanase pipeline drugs market?
The key mechanism of action of the Heparanase pipeline drugs market is Heparanase Inhibitor.
-
What are the routes of administration in the Heparanase pipeline drugs market?
The routes of administration in the Heparanase pipeline drugs market are subcutaneous, intravenous, and oral.
-
What are the molecule types in the Heparanase pipeline drugs market?
The molecule types in the Heparanase pipeline drugs market are Small Molecule, Polysaccharide, Peptide and Synthetic Peptide.
-
Which are the key companies in the Heparanase pipeline drugs market?
Some of the key companies in the Heparanase pipeline drugs market are B-Side Pharma Ltd, Beta Therapeutics Pty Ltd, CarboMimetics, HepaRx Ltd, Johnson & Johnson, Leadiant Biosciences Inc, Shenzhen Hepalink Pharmaceutical Group Co Ltd and Zucero Therapeutics Ltd among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.